National Bank of Canada FI Trims Stake in Natera, Inc. $NTRA

Key Points

• National Bank of Canada FI significantly reduced its stake in Natera, Inc. by 79.6%, holding just 804 shares worth $114,000 as per their recent SEC filing.
• Despite the decline in ownership from National Bank, other institutional investors, like Vanguard Group and Price T Rowe Associates, increased their stakes in Natera, indicating ongoing investor interest in the stock.
• Natera reported earnings showing a $0.74 loss per share, missing estimates, but achieved a revenue of $546.60 million, surpassing expectations and representing a 32.2% year-over-year increase.

National Bank of Canada FI decreased its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 79.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 804 shares of the medical research company's stock after selling 3,128 shares during the quarter. National Bank of Canada FI's holdings in Natera were worth $114,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. HighPoint Advisor Group LLC boosted its stake in shares of Natera by 30.8% in the first quarter. HighPoint Advisor Group LLC now owns 1,986 shares of the medical research company's stock valued at $308,000 after buying an additional 468 shares during the period. Amalgamated Bank boosted its stake in shares of Natera by 9.8% in the first quarter. Amalgamated Bank now owns 8,293 shares of the medical research company's stock valued at $1,173,000 after buying an additional 740 shares during the period. GAMMA Investing LLC boosted its stake in shares of Natera by 32.3% in the first quarter. GAMMA Investing LLC now owns 848 shares of the medical research company's stock valued at $120,000 after buying an additional 207 shares during the period. Teza Capital Management LLC bought a new stake in shares of Natera in the fourth quarter valued at approximately $221,000. Finally, Asset Management One Co. Ltd. bought a new stake in shares of Natera in the first quarter valued at approximately $6,753,000. Institutional investors and hedge funds own 99.90% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on NTRA. Barclays restated an "overweight" rating and set a $210.00 target price (up from $190.00) on shares of Natera in a research note on Friday, August 8th. UBS Group increased their price objective on Natera from $211.00 to $218.00 and gave the company a "buy" rating in a report on Friday, May 9th. Royal Bank Of Canada increased their price objective on Natera from $251.00 to $255.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Wall Street Zen downgraded Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. Finally, Morgan Stanley reiterated an "overweight" rating and set a $195.00 price target on shares of Natera in a report on Sunday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating and seventeen have assigned a Buy rating to the stock. Based on data from MarketBeat.com, Natera has an average rating of "Buy" and a consensus target price of $193.19.

Natera Trading Up 2.0%

Shares of NTRA stock traded up $3.2140 during trading hours on Friday, hitting $165.1640. 462,226 shares of the company were exchanged, compared to its average volume of 1,512,639. The firm has a fifty day simple moving average of $154.84 and a 200 day simple moving average of $154.38. Natera, Inc. has a 52-week low of $110.57 and a 52-week high of $183.00. The stock has a market capitalization of $22.67 billion, a price-to-earnings ratio of -86.47 and a beta of 1.76.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The business had revenue of $546.60 million during the quarter, compared to analysts' expectations of $476.84 million. During the same quarter in the prior year, the firm posted ($0.30) earnings per share. The firm's quarterly revenue was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Insider Activity

In other news, insider Solomon Moshkevich sold 3,000 shares of the business's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $157.07, for a total transaction of $471,210.00. Following the completion of the transaction, the insider directly owned 133,205 shares in the company, valued at $20,922,509.35. The trade was a 2.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Michael Burkes Brophy sold 3,045 shares of the business's stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $137.40, for a total transaction of $418,383.00. Following the transaction, the chief financial officer owned 65,430 shares of the company's stock, valued at $8,990,082. This trade represents a 4.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 61,792 shares of company stock valued at $9,227,972 over the last 90 days. Company insiders own 5.63% of the company's stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.